ME/CFS Science @mecfsscience.org · 17/09/20266) BioVie, however, points to results of subgroup analyses. If they restrict the comparison to participants who had a high symptom score at baseline, they did find effects favouring Bezisterim (but still with large confidence intervals). 180
ME/CFS Science @mecfsscience.org · 17/09/20267) A big question is: was this analysis planned in advance or they did go searching for a good result in the data? I couldn't find it in the protocol or trial registration but BioVie says the analysis was pre-specified in what they submitted to the FDA. 2100
ME/CFS Science @mecfsscience.org · 17/09/20268 ) It's interesting that most outcomes favour the Bezisterim group. Although there were reportedly few side-effects, it could be that some broke the blinding so that patients knew that they were on the drug. That's a potential limitation. 180
Fiona C @drfionac.bsky.social · 17/09/2026Exactly my question when I saw that second graph there! 🧐 010
